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Smry Monoclonal antibody MUC 2-63 recognses neuroenic tumours and has been used successfilly for
radiimaging human malignant ghomas. We now show that the MUC 2-63 antigen has the same tissue
distibution and molecular weght rae as the CD44 antigen and confirm the identity of these two molecule
in bcking studies using MUC 2-63 and the CD44 anti-framework antibody FIO44-2. Thus not only MUC
2-63 but also other anti-CD44 monodcnal antibodies should prove useful in imaging and, perhaps, therapy of
brain tumours.
The CD44 molecule was orginally defined by the mono-
clonal antibody FIO 442 and found predominantly on lym-
phohaemopoietic tissues and brain (Dalhau et al., 1980,
Stoll et al., 1989). In man the CD44 antigen is expressed on
T and B lymphocytes, granulocytes, monocytes/macrophages
and the majority of erythrocytes (reviwed in Haynes et al.,
1989; Stamenkovic et al., 1989). It is acquired by medullary
thymocytes during T-cell maturation in the thymus and is
up-regulated on memory T cells (Dalchau et al., 1980;
Haynes et al., 1983; Sanders et al., 1988). CD44 is also
present at low levels on normal epithelium, but is highly
expressed on carcnomas, including those of the colon (Daar
& Fabre, 1983; Stamenovic et al., 1989). In human brain
the molecule has a molkeular weight of 90kDa, while a
lymphoid form of 80-90kDa (CD44H) and an epitheial
form of 160 kDa (CD44E) have been described (McKenzie et
al., 1982; Stamenkovic et al., 1989, 1991; Brown et al., 1991).
The diferences between these and other isoforms, ranging in
molcular weight from 85 to 250 kDa, lie in the membrane-
proximal region and result from alternative splicing of at
least ten different exons and from post-translational
modifications (Brown et al., 1991; Jackson et al., 1992;
Screaton et al., 1992; Tolg et al., 1993).
Many functions involving cell-cell and cell-extracellular
matrix interactions have been attributed to CD44, and are
likely to be mediated by different isoforms (Belitsos et al.,
1990; Staovic et al., 1991; Jalkanen & Jalkanen, 1992).
Such interactions play a role in cell development, activation
and migration (Berg et al., 1989; Miyake et al., 1990; Ritter
& Crispe, 1992; Haegel et al., 1994). Differential expression
of CD44 variants has been observed on some epithelial,
neuronal and lymphoid tumour cells compared with their
normal counterparts, and between metastatic and non-meta-
static tumours; this may prove usefu in diagnois and disease
evaluation (Matsumura & Tarin, 1992; Koopman et al.,
1993; Salmi et al., 1993). Moreover, there is compelling
evidence in support of a role for CD44 in tumorigenesis in
the rat, in which expson of the p-meta-I splice variant
confers metastatic potential on tumour cells that were
previously non-metastatic (Glinthert et al., 1991).
The monoclonal antibody MUC 2-63 was one of a panel
of antibodies raised to human glioma cells in an attempt to
generate antibodies useful for the typing ofbrain tumours. It
reacted with a cell-surface molecule on gliomas, neuroblas-
tomas and melanomas, as well as with embryonic and fetal
brain, but did not recognise any of the non-neurogenic
tumour cell lines studied (mcluding breast, gastric and col-
onic carcinoma) and did not bind to normal brain apart from
a few cells bordering on the tumour tissue (Stavrou et al.,
1987). Radiolabelled MUC 2-63 was subsequently success-
fully used in vivo for ig of glioma (Bergh et al., 1990;
Stavrou et al., 1991). Although preliminary biochemical
analysis of the MUC 2-63 antigen yielded moleular weights
from 80 to 190 kDa, the exact nature of the molecule
detected by MUC 2-63 was not known (Stavrou et al.,
1990).
We recently included MUC 2-63 in a panel of antibodies
that was used to study tumours of the sk-in and colon.
Surpringly, the antigen detected by MUC 2-63 was found
to be present throughout all the tissues analysed. We have
therefore analysed further the expression of this antigen in
both tumour and normal ftis using immunohistochemical
and flow cytometric techniques and have detrmined the
molecular weight of the molecule by Western blotting. Our
data show a striking similarity to data published for the
CD44 antigen. Subsequent blocking experiments with MUC
2-63 and the anti-CD44 antibody FIO44-2 confirmed the
specificity of MUC 2-63 as an anti-CD44 antibody.
Tissues
Human colon and skin biopsies were from the Royal Sussex
County HospitaL Brighton, tonsils were from St Mary's Hos-
pitaL London, and peiatrc thymus samples were obtained
from childr undergoing cardiac surgery at Great Ormond
Street HospitaL London. Tissues for immunohistochemistry
and biochemistry were snap frozen and stored in liquid nitro-
gen. Cryostat sections were cut at 6 m dried overnight,
fixed for 10 min in absolute acetone, and either used immed-
iately or stored at - 20C until use. For flow cytometric
analysis, fresh thymus and tonsil were teased into single-cell
suspension in phsphate-buffered saie (PBS) and washed
before use. To obtain pereral ood mononuclear cells
(PBMCs), 10 ml of blood containing 200 units of heparin
(Flow, UK) was layered over Ficoll-Hypaque (Sigma, UK)
and centrifuged at 2,000 r.p.m. for 20 min at 4C. The inter-
face PBMCs were removed and washed twice before
immunostainmg.
Antiboes
Prinary antibodis were all mouse monoclonal antibodis,
used either as tissue culture supernatant or as purified Ig,
diluted in Tris-buffered saline (TBS) at a concentration deter-
mined by prior titration. MUC 2-63 is an IgGI monoclonal
antibody (Stavrou et al., 1987). Two independent prepara-
tions were produced from separate cell stocks and used as
supernatant (London) and purified IgG (Hamburg); these
gave identical results in all experimental systems. Antibodies
for FACS analysis were: anti-CD3 (1:10; Dakopatts, Den-
mark), anti-CD22 (1:10; Dakopatts), anti-macrophage (1:10;
Dakopatts) and fluorescein-conjugated anti-CD4 (CD44-
FITC, 1:5; Serotec, UK). An irrelevant isotype-matched
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antibody was used as negative control in immunostaining.
MR6, an IgGI antibody that detects a 200 kDa molecule on
the surface of most thymocytes, tonsillar lymphocytes and
PBMCs, was used as the control for the blocking studies
(Larche et al., 1988). The secondary antibody for immunohis-
tochemistry was peroxidase-conjugated rabbit anti-mouse Ig
(RAM-PX, 1:20; Dakopatts). For FACS analysis, RAM-
FITC (1:20; Dakopatts) was used.
Immunolabelling
Tissue sections were stained by either indirect immunoperox-
idase or immunofluorescence techniques (De Maagd et al.,
1985; Mat et al., 1990). For suspension analysis, 1 x 106 cells
were labelled by indirect immunofluorescence and analysed
by flow cytometry (EPICS Profile, Coulter, USA) (Larche et
al., 1988). RAM-PX and RAM-FITC secondary reagents
were preincubated in 5% human serum to remove cross-
reactivity with endogenous human Ig.
SDS-PAGE and Western blotting
Cryostat sections (10 x 9;Lm) were lysed in 50jl of lysis
buffer (10mM Tris-HCI, pH 7.2, 0.15 M sodium chloride,
0.5% Nonidet P-40, 1 mM PMSF) for 15 min at 4C. Lysates
were centrifuged at 13,000 g for 4 min at 4C. Supernatant
proteins were then separated on a 7.5% polyacrylamide gel
(SDS-PAGE; Laemmli, 1970) and analysed by Western blot-
ting using MUC 2-63, followed by RAM-PX and the subs-




On thymus sections MUC 2-63 showed strong staining of all
medullary thymocytes and small scattered groups of cortical
thymocytes (Figure lb). It also labelled blood vessels and
Hassall's corpuscles, but no other thymic epithelium. On
tonsil sections MUC 2-63 strongly stained B- and T-cell
areas, blood vessels, epithelial cells and follicular dendritic
cells; however, the germinal centre region stained less
intensely than the outer areas of the follicle (Figure Id).
In all seven normal and adenoma colon samples tested
MUC 2-63 gave moderate to strong staining of both
epithelium and lamina propria. Seven of the nine colonic
carcinomas were also moderately to strongly MUC 2-63
positive, while in two the epithelium was only weakly positive
(Table I). Similarly, all normal skin and naevi samples and
11 of 14 basal cell carcinomas (BCCs) showed strong staining
with MUC 2-63, the remaining three being only weakly
positive (Table I, Figure If). In eight of the BCCs only a
proportion of the tumour cells were positive (-50%).
The staining patterns seen with anti-CD44-FITC were
indistinguishable from those given by MUC 2-63 (Figures la,
c and e).
Western blotting analysis ofthe MUC 2-63 antigen
Thymus lysates gave a single band at -90 kDa. Normal
colon gave a major band at 9-% kDa and a minor band at
-137 kDa which was not visible on all blots, probably
because of differences in the amount of protein loaded
(Figure 2). Similarly, colon adenoma showed a major
(- 180 kDa) and a minor (-90 kDa) band, while colonic
carcinoma gave bands at -150 kDa (major component) and
-90 kDa (minor component). Since the -90 kDa bands on
both adenoma and carcinoma were weak they could repre-
sent breakdown product of the larger, major, band; alterna-
tively, they could represent infiltrating leucocytes. BCC also
gave two bands, at -96 kDA and -143 kDa (not
shown).
Table I Analysis ofMUC 2-63 antigen expression in tumours ofskin
and colon
Labelling with MUC 2-63 monoclonal antibody
Tissue (n)' Epithelium Dermis Laminapropria
Normal skin + + + + + + N/A
Naevus (3) + + + + + + N/A
BCC (14) + + /+ + + + + '+ + + N/A
Normal colon + + N/A + +
(3)
Colonic ++I+++ N/A +++++
adenoma (6)
Colonic + +++++ N/A ++ +++
carcinoma (9)
'Number of sampks analysed. +, ++,+++ denotes intensiy of
labelling (weak, moderate, strong). N/A, not applicable.
Flow cytometric analysis
The surface expression of the MUC 2-63 antigen on thymo-
cytes, tonsillar leucocytes and PBMCs was analysed by flow
cytometric analysis. Anti-CD3 (T lymphocytes), anti-CD22
(B lymphocytes) and anti-macrophage antibodies were used
to define leucocyte subpopulations. MUC 2-63 stained the
majority of cells in all three cell preparations (Table II), in
agreement with the data obtained with tissue sections.
Since the cellular distribution and biochemical characteris-
tics of the MUC 2-63 antigen were strikingly similar to those
previously described for CD44, this raised the possibility that
MUC 2-63 was an anti-D44 antibody. To test this hypothe-
sis, blocking experiments were performed using MUC 2-63
and the anti-CD44 monoclonal antibody F1O-44-2 (CD44-
FITC). Preincubation of cells with MUC 2-63 completely
inhibited the subsequent binding of CD44-FITC (Table II).
An isotype-matched control monoclonal antibody, MR6,
which bound to > 50% of the cells in each of the prepara-
tions used, had no effect on CD44-FITC binding. Similar
antibody blocking data were obtained with tumour tissue
using MUC 2-63 followed by CD44-FITC on frozen sec-
tions of basal cell carcinoma (Figure Ig and h).
Diso
Monoclonal antibody MUC 2-63 was one of several reagents
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Figm 2 Western blotting analysis of MUC 2-63 antigen. Tissue
lysates were run on a 7.5% SDS-PAGE gel, blotted onto nylon
membrane and stained with MUC 2-63 followed by peroxidase-
conjugated rabbit anti-mouse Ig and DAB. Lane l, normal
thymus; lane 2, colon carcinoma; lane 3, colon adenoma; lane 4,
normal colon.MUC 2-63 ANTIBODY DETECTS CD44 ANTIGEN 801
Fgwe 1 a-f, Immunofluorescent labelling with antibodies MUC 2-63 (b, d and f) and anti-CD44 (a, c and e) showing
indistinguishable staining patterns on frozen sections of thymus (a and b), tonsil (c and d) and basal cell carcinoma (e and f). MUC
2-63 binding was detected in indirect immunofluorescence using FITC-conjugated rabbit anti-mouse Ig. CD44 was detected either
by indirect immunofluorescence (a, c and e) or by direct immunofluorescence using FITC-anti-CD44 (g and h). Preincubation with
MUC 2-63 blocks the subsequent binding of FITC-anti-CD44 (h), indicating that the two antibodies recognise the same target
antigen. Magnification bar. 25 sum.
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Table n Reactivity of monoclonal antibody MUC 2-63 with
leucocytes from thymus, tonsil and PBMC and its ability to block
binding of CD44-FITC
Antibody Tonsil PBMC Thymdus
Negative control 5.1a 1.5 2.7
Anti-CD22 (B cells) 55.0 9.6 2.0
Anti-CD3 (T cells) 39.3 39.6 67.3
Anti-macrophage 5.3 1.4 2.6
MUC 2-63 88.8 74.8 72.9
MR6 57.1 ND 55.7
Anti-CD44 64.5 64.7 26.9
MUC 2-63 anti-CD44b 1.3 0.0 0.9
MR6 anti-CD44' 69.4 62.9 34.7
aPercentage positive cells by flow cytometric anaylsis. 'Cells were
preincubated with MUC 2-63 prior to addition of anti-CD44-FITC
antibody. 'Cells were preincubated with MR6 prior to addition of
anti-CD44-FITC antibody.
onginal study it was shown to react with gliomas, neuroblas-
tomas and melanomas. but not with any of the non-neuro-
genic tumours tested. MUC 2-63 was subsequently successfully
used in in vivo radioimaging (Bergh et al., 1990).
We included MUC 2-63 in a recent study of epithelial
tumours of skin and colon as part of an ongoing analysis of
epithelial antigen expression dunng tumorigenesis (Mat et al.,
1990. 1993). All antibodies in this study were tested on
sections of human thymus as a positive control for the
immunoperoxidase staining. Surprisingly. MUC 2-63 strongly
labelled small groups of cortical and all medullary thymo-
cytes. suggesting that the MUC 2-63 antigen is acquired with
T-lymphocyte maturation. This was further analysed in tonsil
and PBMC preparations. in which MUC 2-63 was found to
label mature T and B lymphocytes and macrophages. Analysis
of tumour tissue revealed MUC 2-63 antigen on epithelium.
connective tissue and infiltrating leucocytes in all samples
studied, although there was some variation in the intensity
and in the proportion of epithelial cells within a tumour that
were labelled. The molecular weight of the molecule recog-
nised by MUC 2-63 in these tissues was analysed by Western
blotting on thymus. colon and skin lysates. These experi-
ments showed that the antigen is expressed in two main
molecular weight forms of -90 kDa and - 150 kDa.
These molecular weight data were strongly reminiscent of
data previously published for CD44, with a lymphoid form
of 80-90 kDa and an epithelial form of 160 kDa resulting
from alternative exon splicing (Stamenkovic et al.. 1989:
Jackson et al., 1992; Tolg et al., 1993). In addition to these
two cell-specific isoforms, several minor forms ranging in
molecular weight from 50 kDa to 200 kDa and variably pre-
sent on different cell types have been described (Stamenkovic
et al., 1989; Guinthert et al., 1991; Jackson et al., 1992). We
also saw additional minor bands on some Western blots.
Moreover, cell distribution data for MUC 2-63 also match-
ed that reported for CD44. Thus both antigens are acquired
during thymocyte maturation and are present on mature T
and B lymphocytes, monocytes,macrophages, connective tis-
sue and colorectal tumours (Dalchau et al., 1980; McKenzie
et al., 1982; Haynes et al., 1983; Daar & Fabre, 1983; Stoll et
al.. 1989). Our previous failure to detect MUC 2-63 on
epithelial tumours resulted from the use of cell lines rather
than fresh tumour samples as used in the current study
(Stavrou et al., 1987).
Our data therefore strongly suggested that MUC 2-63
detects an epitope present on all CD44 molecules. Blocking
experiments using a well-characterised anti-'framework' anti-
CD44 monoclonal antibody, F10-44-2, confirmed this specifi-
city. The expression of MUC 2-63 on human malignant
gliomas and neuroblastomas has important implications.
Firstly, and as previously demonstrated, the molecule pro-
vides an effective target for in vivo imaging of brain tumours
and, if administered intratumorally or intrathecally, may pro-
vide effective immunotherapy for these tumours (Bergh et al..
1991). Secondly, the MUC 2-63/CD44 molecule may be
involved in tumour development, possibly controlling cell
growth or migration via interactions with the extracellular
matnrx (Stamenkovic et al., 1991; Jalkenen & Jalkenen, 1992:
Knudson et al.. 1993). Thus MUC 2-63 and other anti-CD44
monoclonal antibodies should also provide useful tools with
which to study tumonrgenesis in the brain.
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